# Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

> **NCT06879145** · PHASE2,PHASE3 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 840 (estimated)

## Conditions studied

- Muscular Invasive Bladder Cancer (MIBC)

## Interventions

- **DRUG:** SHR-A2102；Adebrelimab

## Key facts

- **NCT ID:** NCT06879145
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-25
- **Primary completion:** 2031-12
- **Final completion:** 2031-12
- **Target enrollment:** 840 (ESTIMATED)
- **Last updated:** 2025-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06879145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06879145, "Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06879145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*